HN2008000497A - Composicion farmaceutica fotoestable que contiene brivudina para el tratamiento de la queratitis herpetica - Google Patents

Composicion farmaceutica fotoestable que contiene brivudina para el tratamiento de la queratitis herpetica

Info

Publication number
HN2008000497A
HN2008000497A HN2008000497A HN2008000497A HN2008000497A HN 2008000497 A HN2008000497 A HN 2008000497A HN 2008000497 A HN2008000497 A HN 2008000497A HN 2008000497 A HN2008000497 A HN 2008000497A HN 2008000497 A HN2008000497 A HN 2008000497A
Authority
HN
Honduras
Prior art keywords
treatment
cheratitis
herpetic
pharmaceutical composition
composition containing
Prior art date
Application number
HN2008000497A
Other languages
English (en)
Inventor
Marc Wihsmann
Reinhard Schmitz
Original Assignee
Berlin Chemie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlin Chemie Ag filed Critical Berlin Chemie Ag
Publication of HN2008000497A publication Critical patent/HN2008000497A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCION TRATA DE COMPOSICIONES FARMACEUTICAS QUE CONTIENEN EL ANTIVIRAL BRIVUDINA, UTILES PARA EL TRATAMIENTO DE CONDICIONES INFLAMATORIAS OCULARES, PARTICULARMENTE LA QUERATITIS ESTROMAL INDUCIDA POR EL VIRUS DEL HERPES SIMPLE TIPO 1 (HSV-1) O POR EL VIRUS DE LA VARICELA-ZOSTER (VZV).LAS COMPOSICIONES PERMITEN LA FOTOPROTECCION DEL ANTIVIRAL CON EXCELENTE TOLERANCIA Y ADMINISTRACION PROLONGADA DE LA BRIVUDINA
HN2008000497A 2005-09-29 2008-03-27 Composicion farmaceutica fotoestable que contiene brivudina para el tratamiento de la queratitis herpetica HN2008000497A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005046769A DE102005046769A1 (de) 2005-09-29 2005-09-29 Lichtstabile, brivudinhaltige pharmazeutische Formulierung zur Behandlung von Augenherpes (Herpes Ophthalmicus)

Publications (1)

Publication Number Publication Date
HN2008000497A true HN2008000497A (es) 2010-09-10

Family

ID=37561306

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2008000497A HN2008000497A (es) 2005-09-29 2008-03-27 Composicion farmaceutica fotoestable que contiene brivudina para el tratamiento de la queratitis herpetica

Country Status (33)

Country Link
US (1) US20080249061A1 (es)
EP (1) EP1940353B1 (es)
JP (1) JP2009509993A (es)
KR (1) KR20080053319A (es)
CN (1) CN101272765A (es)
AP (1) AP2008004394A0 (es)
AR (1) AR056551A1 (es)
AT (1) ATE489076T1 (es)
AU (1) AU2006299115A1 (es)
BR (1) BRPI0616449A2 (es)
CA (1) CA2624111A1 (es)
CR (1) CR9839A (es)
CY (1) CY1111059T1 (es)
DE (2) DE102005046769A1 (es)
DK (1) DK1940353T3 (es)
EA (1) EA012975B1 (es)
EC (1) ECSP088310A (es)
ES (1) ES2356774T3 (es)
HN (1) HN2008000497A (es)
HR (1) HRP20110085T1 (es)
IL (1) IL190466A0 (es)
MA (1) MA29887B1 (es)
NO (1) NO20081488L (es)
PE (1) PE20070767A1 (es)
PL (1) PL1940353T3 (es)
PT (1) PT1940353E (es)
RS (1) RS51615B (es)
SI (1) SI1940353T1 (es)
TN (1) TNSN08094A1 (es)
TW (1) TW200744664A (es)
UA (1) UA90911C2 (es)
WO (1) WO2007039201A2 (es)
ZA (1) ZA200802729B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009006130A2 (en) * 2007-06-28 2009-01-08 Bausch & Lomb Incorporated Salt free hyaluronate ophthalmic solution
US20090196833A1 (en) * 2008-02-06 2009-08-06 Adherex Technologies Inc. Compositions comprising topical dpd inhibitors and methods of using same in the treatment of hand-foot syndrome
DE102009003942A1 (de) * 2009-01-07 2010-07-08 D2O Biosience Group Ltd., Hamilton Verwendung von Deuteriumoxid zur Behandlung Virus-basierter Erkrankungen des Auges
PT2898888T (pt) 2014-01-22 2019-07-16 Visufarma B V Composição que compreende iota-carragenina contra conjuntivite viral
JP6941157B2 (ja) * 2016-05-06 2021-09-29 サックシュ・コーポレーション 眼科用組成物
CN113712928A (zh) * 2021-09-29 2021-11-30 重庆市力扬医药开发有限公司 经口腔粘膜吸收的溴夫定药物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY136633A (en) * 2001-01-17 2008-11-28 Berlin Chemie Ag Stabilized brivudine topical formulations
DE10162593A1 (de) * 2001-12-19 2003-07-03 Menarini Ricerche Spa Stabilisierte topische Brivudin-Formulierungen

Also Published As

Publication number Publication date
CA2624111A1 (en) 2007-04-12
DE602006018505D1 (de) 2011-01-05
AR056551A1 (es) 2007-10-10
DK1940353T3 (da) 2011-01-24
ECSP088310A (es) 2008-05-30
BRPI0616449A2 (pt) 2011-06-21
JP2009509993A (ja) 2009-03-12
PL1940353T3 (pl) 2011-05-31
EP1940353A2 (en) 2008-07-09
NO20081488L (no) 2008-03-26
PE20070767A1 (es) 2007-08-13
EA012975B1 (ru) 2010-02-26
DE102005046769A1 (de) 2007-04-05
ATE489076T1 (de) 2010-12-15
AU2006299115A1 (en) 2007-04-12
US20080249061A1 (en) 2008-10-09
TW200744664A (en) 2007-12-16
CR9839A (es) 2008-10-31
PT1940353E (pt) 2011-02-25
WO2007039201A3 (en) 2007-10-04
ES2356774T3 (es) 2011-04-13
AP2008004394A0 (en) 2008-04-30
EP1940353B1 (en) 2010-11-24
HRP20110085T1 (hr) 2011-03-31
UA90911C2 (ru) 2010-06-10
MA29887B1 (fr) 2008-10-03
CN101272765A (zh) 2008-09-24
EA200800646A1 (ru) 2008-10-30
IL190466A0 (en) 2008-11-03
ZA200802729B (en) 2009-09-30
CY1111059T1 (el) 2015-06-11
TNSN08094A1 (en) 2009-07-14
RS51615B (en) 2011-08-31
AU2006299115A2 (en) 2008-05-29
KR20080053319A (ko) 2008-06-12
SI1940353T1 (sl) 2011-03-31
WO2007039201A2 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
HN2008000497A (es) Composicion farmaceutica fotoestable que contiene brivudina para el tratamiento de la queratitis herpetica
WO2007020193A3 (en) Antiviral phosphoramidates of 4 ' -substituted pronucleotides
ECSP099465A (es) Polimorfos de sal de succinato 2-[6-(3-amino-piperidin-1-ilo)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo y métodos
MX2022016405A (es) Análogos de nucleósido de 1¿-ciano y usos de estos.
PE20170679A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales
ECSP099462A (es) Aril fosforamidatos de nucleosido y su uso como agentes antivirales para el tratamiento del virus de la hepatitis c
NI200500090A (es) Compuestos de benzofurano, composiciones y metodos para tratamiento y profilafixis de infecciones virales de hepatitis c y enfermedades asociadas
ECSP14028051A (es) Compuestos d-aminoácidos para enfermedad hepática
UY30004A1 (es) Metodos y kits para dosificar nucléosidos antivirales beta-d-2´, 3´-didehidro-2´, 3´- dideoxi-5-fluorocitidina
PE20161067A1 (es) Analogos carba-nucleosidicos para tratamiento antiviral
CR8935A (es) Inhibidores de la arn polimerasa dependiente del arn del virus de la hepatitis c y composiciones
NI201300107A (es) Derivados de nucleósidos 2' - sustituidos y métodos de uso de los mismos para el tratamiento de enfermedades virales.
CR10192A (es) Compuestos de amido y su uso como productos farmaceuticos
BRPI0414062B8 (pt) uso de ciclosporinas modificadas para o tratamento de distúrbios por hcv
DOP2006000169A (es) Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
UY29516A1 (es) Derivados de purina
UY31470A1 (es) Compuestos que contienen quinoxalina como inhibidores del virus de la hepatitis c
CO6531469A2 (es) Derivados de purina o deazapurina utiles para el tratamiento de (entre otros) infecciones virales
ATE526331T1 (de) Pyrrolopyrimidine für pharmazeutische zusammensetzungen
NI201100076A (es) Péptidos antivirales terapéuticos.
CR20130172A (es) Análogos de carba-nucleósidos sustituidos con 2'-fluoro para tratamiento antiviral
UY30392A1 (es) Compuestos de oximilo macrociclico inhibidores de proteasa de hepatitis c
CL2008000959A1 (es) Compuestos derivados de 1,2,4-tiadiazina o 1,4-tiazina; composiciones farmaceuticas que los contienen; y su uso para la prevencion y/o tratamiento de infecciones producidas por el virus de la hepatitis c.
GT200600144AA (es) 1h-quinazolin-2,4-dionas (solicitud fraccionaria, derivada de la solicitud de patente de invencion pi-2006-00144)
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos